Khatib T Z, Martin K R
Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Eye Department, Addenbrooke's Hospital, Cambridge, UK.
Eye (Lond). 2017 Feb;31(2):218-224. doi: 10.1038/eye.2016.299. Epub 2017 Jan 13.
Retinal ganglion cell degeneration underlies several conditions which give rise to significant visual compromise, including glaucoma, hereditary optic neuropathies, ischaemic optic neuropathies, and demyelinating disease. In this review, we discuss the emerging strategies for neuroprotection specifically in the context of glaucoma, including pharmacological neuroprotection, mesenchymal stem cells, and gene therapy approaches. We highlight potential pitfalls that need to be considered when developing these strategies and outline future directions, including the prospects for clinical trials.
视网膜神经节细胞变性是导致严重视力损害的多种病症的基础，这些病症包括青光眼、遗传性视神经病变、缺血性视神经病变和脱髓鞘疾病。在本综述中，我们将讨论特别是在青光眼背景下的新兴神经保护策略，包括药理学神经保护、间充质干细胞和基因治疗方法。我们强调在制定这些策略时需要考虑的潜在陷阱，并概述未来的方向，包括临床试验的前景。
